While the increased insulin/PI3K/AKT signal in the liver leads to improved systemic insulin sensitivity (88), the resulting NASH due to increased de novo lipogenesis however forms an environment that results in damage of the liver parenchymal (138–142). The gene discussed is AKT1; the disease is metabolic dysfunction-associated steatohepatitis.